Tumor heterogeneity, the diverging evolution of both different subparts of primary tumors and of metastases compared to the primary tumor, is often named among the challenges for targeted treatment.more »
LONDON A $1 billion program to develop vaccines against emerging infectious diseases that, like Zika and Ebola viruses, have the potential to cause serious epidemics, will be launched at the World Economic Forum in Davos, Switzerland.more »
DUBLIN – Forward Pharma A/S is banking a $1.25 billion cash payment from Biogen Inc. in a partial settlement of their intellectual property dispute over the use of dimethyl fumarate for treating multiple sclerosis, and it could also be in line to pocket future royalties from sales of Biogen's Tecfidera product.
If intervening ahead of symptoms in Alzheimer's disease (AD) works in people with gene mutations that predispose them to getting sick at a younger age, then it will probably work in the rest of the population, principal investigator Randall Bateman theorized to BioWorld Today.more »
- Post-Questcor, Mallinckrodt pays $100M to settle Acthar antitrust charge
- Cytori taps Azaya for potential revenue, nanotech platform
- PASIng lane? Dermira wins again with Cimzia phase III; high dose conquers Enbrel
- In some tumors, heterogeneity only in passenger mutations
- Octimet closes $12M series A round for oral Met ...
SAN FRANCISCO – The regenerative medicine sector continues to actively build, remarked Morrie Ruffin, managing director of the Washington-based Alliance for Regenerative Medicine's (ARM), in introducing the 2017 state of the industry briefing presented at the Biotech Showcase conference. Not only is that being reflected by the size of the industry but also in the attendance at ARM's annual event, now in its seventh year.
"Basically, it's not easy to define what will serve humanity."
So said Yoshinori Ohsumi, honorary professor at the Tokyo Institute of Technology, after winning the 2012 Kyoto Prize in Life Sciences for his research.
The Nobel Assembly followed suit in recognizing the importance of Ohsumi's work, awarding him the 2016 Nobel Prize in Physiology or Medicine to "for his discoveries of mechanisms for autophagy."READ MORE »
- New targets for overcoming melanoma resistance identified »
- Dual-action, dual-indication decoy fights tumors, viruses »
- Stem cell-based model suggests deafness treatments »
- Stabilizing MLL fights fusion proteins' effects »
- Platelet activation blocker affects clotting more than bleeding »
- Stem cell strategy boosts testosterone »
- Depressed patients are less responsive to chemotherapy »
- Ribociclib ups survival in postmenopausal Asian women with advanced breast cancer »
- CRISPR goes massively multiplex, further expanding reach »
- Yes, there’s a doctor in the House (and Senate)January 04, 2017 | 12:21 AM | Posted by: Mari Serebrov
- Time for fa-la-la with BioWorld’s 10th annual Holiday Gift GuideDecember 02, 2016 | 8:43 PM | Posted by: Marie Powers
- Biotech’s biggest protesters are turning into its supporters November 30, 2016 | 10:58 PM | Posted by: Amanda Lanier
- Sex and drugs: Something doesn’t ‘Addyi’ upNovember 04, 2016 | 10:35 PM | Posted by: Randy Osborne
- Rules of the PAP road not always clear, even to seasoned travelersOctober 25, 2016 | 11:37 PM | Posted by: Marie Powers
Partners in Focus
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST